Tryptamine’s TRP-8802 Shows Promise in IBS Trial

Tryptamine Therapeutics (AU:TYP) has released an update.

Tryptamine Therapeutics has released positive interim results from its Phase 2a trial of TRP-8802 at Massachusetts General Hospital, showing 75% of IBS patients experienced a significant reduction in abdominal pain and anxiety. This promising data supports the potential of TRP-8803, an innovative IV-infused psilocin therapy, to target IBS and other conditions effectively. The results also highlight TRP-8803’s advantages over oral psilocybin, offering faster onset and controlled psychedelic effects, positioning it as a competitive player in the market.

For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.